Novartis AG (NOVN) short interest & options flow
SWXNovartis heads into the final stretch of Q3 with a 7% monthly pullback, a clean borrow market, and Q4 earnings on the horizon — the tension is whether the stock's defensive credentials can hold while momentum softens. The price action this month tells a clear story of pressure followed by partial recovery. NOVN closed at CHF 113.84 on September 15, down 7% from a month ago, though…
NOVN cost to borrow soars 187% in one week to 1.96%, driven by tightening lending conditions on the Swiss pharma giant.
- Market cap
- $308.88B
- Next earnings
- 3 Feb 2027
Key data as of 5 Nov 2026
Latest signals on NOVN
- Cost to Borrow
NOVN cost to borrow soars 187% in one week to 1.96%, driven by tightening lending conditions on the Swiss pharma giant.
NOVN Stock Report — available now on ORTEX
A new long-form analysis for NOVN this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumNOVN news and analysis
RSSNo long-form analysis yet for NOVN. Pulse alerts and the live data picture are available on ORTEX.
Open NOVN on ORTEX →Want the live picture for NOVN?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NOVN — free to start on ORTEX.
Sign up for free →Open NOVN on ORTEX